GLTO - Galecto, Inc. Common Stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
11.32 0.18 (1.59%)	---	---	0.0 (0.0%)	-0.51 (-4.51%)	0.94 (8.68%)	-0.3 (-2.54%)	-0.3 (-2.54%)

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Category: PHARMACEUTICAL PREPARATIONS

Market Period: Closed

Earnings & Ratios

Basic EPS:: -2.6
Diluted EPS:: -2.6
Basic P/E:: -4.4231
Diluted P/E:: -4.4231
RSI(14) 1m:: 0.0
VWAP:: 11.5
RVol:: 0.0207

Events

Period	Kind	Movement	Occurred At
1m	Price decrease 1m	11.55 -0.13 (-1.11%)	Oct 15 09:56
1m	Price increase 1m	11.68 +0.18 (+1.57%)	Oct 15 09:55
1m	Price decrease 1m	11.41 -0.19 (-1.6%)	Oct 15 09:43
60m	Price increase 60m	11.59 +0.79 (+7.31%)	Oct 15 09:41
10m	Price increase 10m	11.59 +0.71 (+6.48%)	Oct 15 09:41